FDA Accepts Supplement for SPRAVATO (Esketamine Hydrochloride)
The FDA has accepted a supplemental application for SPRAVATO, indicating ongoing development and potential label expansion.
Company
Pharmaceutical intelligence for Janssen Pharmaceuticals with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.